Skip to main content
Glowing glass vial of TheraSphere Glass Microspheres against blue background.

TheraSphere™ Y-90 Glass Microspheres

About TheraSphere

Powerful Y-90 radiation embedded within each glass microsphere


  • Arrives in a custom-sealed source vial with an easy and safe set-up
  • Administration takes less than five minutes
  • Minimizes residual and no concern for stasis or reflux

See how TheraSphere is made

Precision-manufactured glass microspheres are the most powerful radiation therapy on the market.


Safety and efficacy

TheraSphere is an efficient and powerful HCC therapy that safely delivers high-dose radiation with optimal patient outcomes. TheraSphere’s unique ability to deliver high-dose radiation with fewer spheres allows for maximum absorbed dose and increased tumor response while preserving healthy tissue.¹

And TheraSphere is the only FDA-approved Y-90 treatment for HCC.


Targeted accuracy

Highly versatile and highly powerful, TheraSphere has been proven to downsize and destroy tumors* in patients with HCC.² Precisely formulated glass microspheres, infused with high-dose Y-90 ensures TheraSphere is delivered with targeted accuracy into HCC tumors.


Product specifications and sizes

TheraSphere treatment entails precisely formulated glass microspheres infused with high-dose Y-90, delivered with targeted accuracy into hepatocellular carcinoma (HCC) tumors to improve tumor* response and provide longer overall patient survival. ³,

  • Pure beta emitter
  • Average energy of 0.9367 MeV
  • Average tissue penetration range of 2.5 mm

Powerful interventional radiotherapy

  • Insoluble glass microspheres with a mean diameter of 20-30 µm 
  • Y-90 is an integral constituent of the glass 
  • Standard doses (GBq): 3, 5, 7, 10, 15, & 20, ranging from 1.2 to 8 million microspheres 
  • Custom doses: Between 3 and 20 GBq in 0.5-GBq increments 

Reimbursement

Find coding and economic resources for health care practitioners and their partners.

Have your questions answered

Receive additional information to help determine if TheraSphere could be a treatment option for your patients.


A fight against cancer

They’re fighting for quality of life. TheraSphere is uniquely able to help you strike first on both fronts.

References

  1. Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0.
  2. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y-90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatology. 2017 Dec 1.
  3. LEGACY: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819. Percentage shown reflects patients who were eligible for tumor response assessment.
  4. Garin E, Tselikas L, Guiu B et al. Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021, 6: 17-29.

*Refers to HCC or associated tumors 

TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation.